Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of YTB323 in non-active progressive multiple sclerosis
2024-514006-31-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Apr 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Gene Therapies
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of rapcabtagene autoleucel in multiple sclerosis (MS), secondary-progressive multiple sclerosis (SPMS) and primary progressive multiple sclerosis (PPMS), sponsored by Novartis. Primary endpoint: Safety and dose-limiting toxicity. Planned start Apr 2026; status: authorised.
02
Drugs
rapcabtagene autoleucel
03
Conditions
multiple sclerosis (MS)secondary-progressive multiple sclerosis (SPMS)primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on 2024-514006-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514006-31-00.